Liposome-trimethyl chitosan nanoparticles codeliver insulin and siVEGF to treat corneal alkali burns by inhibiting ferroptosis.
corneal alkali burn
ferroptosis inhibition
insulin
nanomedicine
siVEGF
Journal
Bioengineering & translational medicine
ISSN: 2380-6761
Titre abrégé: Bioeng Transl Med
Pays: United States
ID NLM: 101689146
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
03
08
2022
revised:
05
01
2023
accepted:
27
01
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Alkali burns are potentially blinding corneal injuries. Due to the lack of available effective therapies, the prognosis is poor. Thus, effective treatment methods for corneal alkali burns are urgently needed. Codelivery nanoparticles (NPs) with characteristics such as high bioavailability and few side effects have been considered effective therapeutic agents for ocular diseases. In this study, we designed a new combination therapy using liposomes and trimethyl chitosan (TMC) for the codelivery of insulin (INS) and vascular endothelial growth factor small interfering RNA (siVEGF) to treat alkali-burned corneas. We describe the preparation and characterization of siVEGF-TMC-INS-liposome (siVEGF-TIL), drug release characteristics, intraocular tracing, pharmacodynamics, and biosafety. We found that siVEGF-TIL could inhibit oxidative stress, inflammation, and the expression of VEGF in vitro and effectively maintained corneal transparency, accelerated epithelialization, and inhibited corneal neovascularization (CNV) in vivo. Morever, we found that the therapeutic mechanism of siVEGF-TIL is possibly relevant to the inhibition of the ferroptosis signaling pathway by metabolomic analysis. In general, siVEGF-TIL NPs could be a safe and effective therapy for corneal alkali burn.
Identifiants
pubmed: 36925675
doi: 10.1002/btm2.10499
pii: BTM210499
pmc: PMC10013822
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10499Informations de copyright
© 2023 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.
Déclaration de conflit d'intérêts
The author declare no conflict of interest.
Références
Nanoscale. 2017 Oct 19;9(40):15461-15469
pubmed: 28976519
Int J Pharm. 2018 Oct 5;549(1-2):201-217
pubmed: 30071309
Colloids Surf B Biointerfaces. 2019 Jan 1;173:725-732
pubmed: 30384269
Cell Death Dis. 2016 Nov 10;7(11):e2467
pubmed: 27831562
Anal Chim Acta. 2020 Aug 15;1125:66-75
pubmed: 32674782
Int J Pharm. 2021 Sep 25;607:120924
pubmed: 34324989
Int J Biol Macromol. 2020 Aug 1;156:749-761
pubmed: 32320806
Biomolecules. 2021 Aug 01;11(8):
pubmed: 34439800
Life Sci. 2017 Mar 15;173:1-10
pubmed: 27693383
Nanomaterials (Basel). 2021 Nov 08;11(11):
pubmed: 34835766
Exp Eye Res. 2021 Apr;205:108526
pubmed: 33662355
ACS Appl Mater Interfaces. 2022 Apr 20;14(15):17022-17031
pubmed: 35380773
Int J Biol Macromol. 2022 Apr 1;203:379-388
pubmed: 35104473
Invest Ophthalmol Vis Sci. 2015 Jan 08;56(2):711-21
pubmed: 25574050
Am J Ophthalmol. 2012 Sep;154(3):481-485.e1
pubmed: 22633350
Exp Eye Res. 2021 May;206:108539
pubmed: 33741324
Carbohydr Polym. 2017 Feb 10;157:875-902
pubmed: 27988003
Drug Discov Today. 2021 Jun;26(6):1437-1449
pubmed: 33689858
Am J Pathol. 2005 May;166(5):1405-18
pubmed: 15855641
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Jun 1;1117:136-147
pubmed: 31009899
Exp Eye Res. 2021 Jan;202:108329
pubmed: 33198953
Cornea. 2019 Dec;38(12):1589-1594
pubmed: 31453878
Nanomedicine. 2017 Nov;13(8):2425-2437
pubmed: 28821465
Free Radic Res. 2014 Mar;48(3):347-56
pubmed: 24286466
Protein Cell. 2021 Nov;12(11):836-857
pubmed: 33891303
Cell Death Differ. 2019 Nov;26(11):2284-2299
pubmed: 30737476
Acta Ophthalmol. 2022 Jun;100(4):e912-e919
pubmed: 34407296
Chem Soc Rev. 2021 May 7;50(9):5397-5434
pubmed: 33666625
Pharmaceutics. 2020 Jun 19;12(6):
pubmed: 32575411
Curr Drug Targets. 2020;21(12):1159-1180
pubmed: 32189591
Eur J Pharm Biopharm. 2019 Jul;140:1-10
pubmed: 31015020
Biomed Pharmacother. 2021 Feb;134:111103
pubmed: 33338747
Exp Eye Res. 2021 Jan;202:108363
pubmed: 33221371
Toxicol Rep. 2021 Jun 08;8:1200-1206
pubmed: 34189056
Carbohydr Polym. 2022 Apr 15;282:119100
pubmed: 35123739
Ocul Surf. 2018 Oct;16(4):398-414
pubmed: 29908870
Drug Deliv Transl Res. 2018 Oct;8(5):1127-1138
pubmed: 29869292
J Control Release. 2020 Oct 10;326:192-202
pubmed: 32653503
Am J Pathol. 2020 Nov;190(11):2237-2250
pubmed: 32858016
Prog Retin Eye Res. 2022 Nov;91:101090
pubmed: 35649962
Free Radic Biol Med. 2021 Nov 20;176:149-161
pubmed: 34562609
Theranostics. 2022 Jan 1;12(2):657-674
pubmed: 34976206
Oxid Med Cell Longev. 2020 Jun 21;2020:7435260
pubmed: 32655773
Int J Biol Macromol. 2020 Oct 1;160:470-481
pubmed: 32464212
Environ Toxicol Pharmacol. 2018 Dec;64:155-163
pubmed: 30412861
Small. 2021 Mar;17(11):e2006004
pubmed: 33619841
Transl Res. 2022 Oct;248:111-127
pubmed: 35609782